ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Insmed Initiates ARIKAYCE Trial for MAC Lung Disease americanpharmaceuticalreview
January 11, 2021Insmed announced the first patient was dosed in the frontline clinical trial program of ARIKAYCE? (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). -
EC Grants Authorization for ARIKAYCE Liposomal Nebulizer Dispersion for NTM Lung Infections americanpharmaceuticalreview
November 06, 2020Insmed Incorporated announced the European Commission (EC) has granted marketing authorization for ARIKAYCE? Liposomal 590 mg Nebulizer Dispersion for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium ...
Pharma Sources Insight July 2025
